Acute leukemia of ambiguous lineage with BCL11B rearrangement

Yiannis Petros Dimopoulos,Sanam Loghavi
DOI: https://doi.org/10.1182/blood.2023022709
IF: 20.3
2024-01-12
Blood
Abstract:A 66-year-old man presented with abnormal complete blood count (white blood cell count 28.4 × 10 9 /L, hemoglobin 6.9 g/dL, platelets 54 × 10 9 /L) with 81% blasts. The bone marrow (BM) aspirate showed 79% blasts (panel A, Wright-Giemsa stain, 100× objective), with a subset positive for myeloperoxidase (panel B, 100× objective). The BM biopsy showed sheets of blasts (panel C, hematoxylin and eosin stain, 100× objective). Blasts had a T/myeloid phenotype (panel E, flow cytometry) positive for CD2, cCD3, CD7, CD13, CD33, CD34, CD117, CD123, CD133, HLA-DR, MPO (13%), TDT, and negative for CD1a, sCD3, CD5, CD8. This prompted additional immunohistochemical staining for BCL11B, which was diffusely positive (panel D, 40× objective). Sequencing identified FLT3 internal tandem duplication and TET2 (R1465∗) and RAD21 (L193fs) mutations. Optical genome mapping showed t(8;14)(q24.21;q32.2) with CCDC26 :: SET3 putative fusion gene (panel F), previously shown to lead to BCL11B deregulation due to enhancer hijacking.
hematology
What problem does this paper attempt to address?